

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/517,518
Applicant : S. SPERL
Filed : July 1, 2005
TC/A.U. : 1621
Examiner : S. KUMAR

Docket No. : 2923-671
Customer No. : 06449
Confirmation No. : 1246

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL
DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The owner, Wilex AG, of 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Serial No. 10/521,805, filed on January 21, 2005, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Statement under 37 C.F.R. 3.73(b)

Wilex AG is the assignee of 100% percent interest in the instant application, by virtue of an assignment recorded in the U.S. Patent and Trademark Office at Reel 015716 and Frame 0897.

The undersigned, whose title is supplied below, is empowered to act on behalf of the owner.

Declaration

The undersigned hereby declares that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

By: _____

Signature

Typed Name: _____

Prof. Dr. Olaf G. Wilhelm
Chief Executive Officer

Typed Title: _____

Date: _____

27. January 2009

1565130

WILEX

Focused Cancer Therapies

WILEX AG | Grillparzerstr. 10, 81675 Munich
Tel. +49 (0) 89 413138-0, www.wilex.com